Trials / Completed
CompletedNCT03221933
A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA
Phase Ⅱ Clinical Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for Gestational Age(SGA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 24 Months – 90 Months
- Healthy volunteers
- Not accepted
Summary
To preliminary assess the efficacy and safety of recombinant human growth hormone injection on the treatment of small for gestational age (SGA), and determine the best dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Somatropin Injection low dose group | 0.23mg/kg /wk，inject for seven divided doses |
| BIOLOGICAL | Somatropin Injection high dose group | 0.46mg/kg /wk，inject for seven divided dose |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2014-12-01
- First posted
- 2017-07-19
- Last updated
- 2017-12-12
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03221933. Inclusion in this directory is not an endorsement.